IDH2 and central nervous system cancer: Accumulated evidence indicated that glioma patients with IDH mutation and those with 1p/19q co-deletion were relatively more sensitive to radiotherapy and chemotherapy, as well as had a favorable prognosis (Sabha et al., 2014).